v3.25.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Revenue: | ||||
| Collaboration Revenue | $ 0 | $ 0 | $ 0 | $ 16,000,000 |
| Grant Revenue | 0 | 0 | 0 | 20,000 |
| Total Revenue | 0 | 0 | 0 | 16,020,000 |
| Operating Expenses: | ||||
| General and Administrative | 1,443,827 | 1,380,997 | 4,287,075 | 4,215,411 |
| Research and Development | 2,729,891 | 2,184,991 | 7,852,267 | 5,917,868 |
| Collaboration Credits | (1,658,248) | (867,760) | (5,310,288) | (2,200,298) |
| In-Process R&D Impairment | 0 | 2,008,000 | 0 | 2,008,000 |
| Change in Fair Value of Contingent Consideration | (1,721,033) | (1,103,991) | (1,308,067) | (995,951) |
| Total Operating Expenses | 794,437 | 3,602,237 | 5,520,987 | 8,945,030 |
| Operating (Loss) Income | (794,437) | (3,602,237) | (5,520,987) | 7,074,970 |
| Other Income (Expense), Net: | ||||
| Interest Income, Net | 201,822 | 248,840 | 703,692 | 813,989 |
| Other Expense, Net | (23,708) | (59,929) | (133,517) | (70,724) |
| Total Other Income, Net | 178,114 | 188,911 | 570,175 | 743,265 |
| (Loss) Income Before Income Tax Benefit | (616,323) | (3,413,326) | (4,950,812) | 7,818,235 |
| Income Tax Benefit | 643,129 | 0 | 632,179 | 0 |
| Net (Loss) Income | 26,806 | (3,413,326) | (4,318,633) | 7,818,235 |
| Net (Loss) Income Attributable to Common Shareholders | 26,806 | (3,413,326) | (4,318,633) | 7,818,235 |
| Net (Loss) Income Attributable to Common Shareholders | $ 26,806 | $ (3,413,326) | $ (4,318,633) | $ 7,818,235 |
| Net (Loss) Income per Common Share - Basic (in usd per share) | $ 0.01 | $ (0.81) | $ (1.04) | $ 2.08 |
| Weighted Average Shares Outstanding - Basic (in shares) | 4,289,853 | 4,214,950 | 4,165,568 | 3,757,467 |
| Net (Loss) Income per Common Share - Diluted (in usd per share) | $ 0.01 | $ (0.81) | $ (1.04) | $ 1.91 |
| Weighted Average Shares Outstanding - Diluted (in shares) | 4,361,740 | 4,214,950 | 4,165,568 | 4,092,880 |
| Other Comprehensive (Loss) Income: | ||||
| Net (Loss) Income | $ 26,806 | $ (3,413,326) | $ (4,318,633) | $ 7,818,235 |
| Unrealized Gain (Loss) on Marketable Securities | 11,214 | 76,435 | (16,001) | 73,607 |
| Foreign Currency Translation Adjustments | (9,153) | 94,094 | 54,451 | 33,988 |
| Comprehensive (Loss) Income | $ 28,867 | $ (3,242,797) | $ (4,280,183) | $ 7,925,830 |
| X | ||||||||||
- Definition Collaboration Credit, Operating Expense No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of interest income (expense) classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue that is not accounted for under Topic 606. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|